Plasmacytoid dendritic cell leukemia with potent antigen-presenting ability

Acta Haematol. 2008;120(2):91-9. doi: 10.1159/000165510. Epub 2008 Oct 24.

Abstract

We report 2 patients with plasmacytoid dendritic cell leukemia (pDCL) expressing CD4, CD56, CD33, CD36, HLA-DR, CD123, CD86 and CD83 in the absence of lineage markers (myeloid, B, T or natural killer cells) except for CD33. Culturing leukemic blasts of both cases with IL-3 for 4 days increased the expression of surface molecules associated with antigen presentation, e.g. CD1a and CD40. Leukemic blasts of both cases possessed a considerable level of antigen-presenting ability to allogeneic lymphocytes in mixed leukocyte cultures. Culturing the blasts with IL-3 for 4 days markedly increased allogeneic antigen presenting ability. Combined with data showing evident graft-versus-leukemia effects without graft-versus-host disease in a cord blood stem cell transplanted pDCL case, leukemic cells in pDCL may act as potent antigen presenting cells in vivo, too.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antigen Presentation*
  • Cell Lineage
  • Cord Blood Stem Cell Transplantation
  • Dendritic Cells / immunology*
  • Dendritic Cells / pathology
  • Graft vs Leukemia Effect
  • Humans
  • Immunophenotyping
  • Interleukin-3 / pharmacology
  • Leukemia / immunology
  • Leukemia / pathology*
  • Leukemia / therapy
  • Male

Substances

  • Interleukin-3